Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Other Accumulated Expenses: 2017-2024

Historic Other Accumulated Expenses for UroGen Pharma (URGN) over the last 8 years, with Dec 2024 value amounting to $7.9 million.

  • UroGen Pharma's Other Accumulated Expenses rose 21.70% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year increase of 21.70%. This contributed to the annual value of $7.9 million for FY2024, which is 105.91% up from last year.
  • Per UroGen Pharma's latest filing, its Other Accumulated Expenses stood at $7.9 million for FY2024, which was up 105.91% from $3.9 million recorded in FY2023.
  • UroGen Pharma's 5-year Other Accumulated Expenses high stood at $7.9 million for FY2024, and its period low was $1.9 million during FY2020.
  • Over the past 3 years, UroGen Pharma's median Other Accumulated Expenses value was $3.9 million (recorded in 2023), while the average stood at $5.0 million.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first decreased by 1.62% in 2022, then spiked by 105.91% in 2024.
  • Yearly analysis of 5 years shows UroGen Pharma's Other Accumulated Expenses stood at $1.9 million in 2020, then soared by 79.13% to $3.3 million in 2021, then decreased by 1.62% to $3.3 million in 2022, then rose by 17.83% to $3.9 million in 2023, then spiked by 105.91% to $7.9 million in 2024.